Q&M Dental Group Sets the Gold Standard for Best Investor Relations at Singapore Corporate Awards
- Awarded Best Investor Relations (Gold) for mid-caps (S$300m-S$1bn) - CEO Dr. Ng Chin Siau Shares Insights on Upholding Principles of Transparency, Communication, and Trust
SINGAPORE, Sep 11, 2023 - (ACN Newswire) - Q&M Dental Group Limited is honoured to announce that it has received the prestigious "Best Investor Relations Award (Gold)" at the 18th Singapore Corporate Awards' ceremony held on 7 September 2023. The Award is given in recognition of Q&M Dental Group's commitment to maintaining transparency, communication, and excellence in investor relations.
Dr Ng Chin Siau, Group Chief Executive Officer of Q&M, said, "Winning the Best Investor Relations Award (Gold) is a testament to our unwavering commitment to uphold the highest standards in investor relations. We believe in the principles of transparency, open communication, and ethical conduct.
Our dedicated Finance and Investor Relations team works tirelessly to provide timely and reliable financial reporting, maintain regular communication through various channels, and ensure compliance with all regulatory requirements. For us, this award is not so much a final destination but a responsibility to continue setting benchmarks in investor relations." Dr Ng added that he believes the Company garnered the award because it adheres to the best practices of investor relations which are:
1. Transparency and Disclosure: Transparent financial reporting and strict adherence to regulatory compliance.
2. Effective Communication: Q&M maintains a two-way dialogue with its shareholders and investment community, providing regular updates through press releases, investor meetings, and a dedicated IR section on its website.
3. Credibility and Trust: The accessibility of top management, including Dr. Ng Chin Siau (CEO) and Ms Melanie Ng (CFO), have been a cornerstone in building credibility and trust among investors.
4. Strategic Planning: Q&M Dental Group has been recognized for its clear communication of long-term vision and risk management strategies.
ShareInvestor and Waterbrooks Consultants are proud to be Q&M 's Investor Relations Partners. ShareInvestor (www.shareinvestorholdings.com) is a leading regional media and technology company, founded in 1999 to empower investors to make informed investment decisions. ShareInvestor focuses on providing investor relations, market data and investor education services, and operates the largest investor relations network in the region. It has over 130 employees in four countries (Singapore, Malaysia, Thailand and Indonesia). Companies in the group includes investor relations/public relations firm, Waterbrooks Consultants Pte Ltd (www.waterbrooks.com.sg), and Investing Note Pte Ltd, Singapore's leading social media platform for investors, (www.investingnote.com).
*Singapore Corporate Awards (SCA) is jointly organised by Institute of Singapore Chartered Accountants (ISCA), Singapore Institute of Directors (SID) and The Business Times (BT). The SCA was launched in 2005 as the umbrella awards for exemplary corporate governance practices for listed companies in Singapore. It seeks to consolidate existing awards while introducing new awards in the area of excellent corporate governance.
The Best Investor Relations Award aims to recognise companies that embody the spirit of good corporate governance and corporate transparency by adopting and implementing best practices in investor relations.
Reference: https://links.sgx.com/FileOpen/20230910_QnMBestIRAwardPressRelease.ashx?App=Announcement&FileID=772006
About Q&M Dental Group (Singapore) Limited (QC7.SI)
Q&M Dental Group (Singapore) Limited (QC7.SI) ("Q&M" or together with its subsidiaries, the "Group") is a leading private dental healthcare group in Asia.
The Group owns the largest network of private dental outlets in Singapore, operating 106 dental outlets across the country. Underpinned by about 270 experienced dentists and over 350 supporting staff, the Group sees an average of 40,000 patient visits a month in Singapore. The Group also operates 5 medical clinics and a dental supplies and equipment distribution company.
Outside of Singapore, the Group has 44 dental clinics and a dental supplies and equipment distribution company in Malaysia. Q&M is also the substantial shareholder of Aoxin Q&M Dental Group Limited, a dental Group listed on the Catalist board of the Singapore Exchange that operates dental clinics and hospitals primarily in the north-eastern region of the PRC. The Group aims to expand its operations geographically and vertically through the value chain in Malaysia, the PRC and within the ASEAN region.
The Q&M College of Dentistry was established in 2019 to offer postgraduate dental education as part of its commitment to continual education and professional development of dentists. It offers Singapore's first private postgraduate diploma programme in clinical dentistry.
In 2020, the Group expanded into the medical laboratories and research industry with the strategic investment into Acumen Diagnostics Pte. Ltd. ("Acumen"). Currently, Acumen focuses on developing its range of medical research, tests and solutions to secure viable patents and to achieve successful commercialisation of the medical products in the near future.
The Group was listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX- ST") on 26 November 2009. For more information on the Group, please visit www.QandMDental.com.sg
Media queries, please contact: Waterbrooks Consultants Pte Ltd Wayne Koo: wayne.koo@waterbrooks.com.sg +65 9338-8166 Derek Yeo: derek@waterbrooks.com.sg +65 9791-4707 General: query@waterbrooks.com.sg
Proud Investor Relations partner: https://www.waterbrooks.com.sg/ and https://www.shareinvestorholdings.com/
Source: Q&M Dental Group Ltd Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm, Local Biz
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
TOPVISION Launches Prospectus for Listing Transfer from LEAP to the ACE Market Nov 27, 2024 05:53 JST
| TOYOTA GAZOO Racing FULLY PREPARED FOR DAKAR 2025 Nov 26, 2024 17:55 JST
| Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan Nov 26, 2024 15:50 JST
| Fujitsu develops Policy Twin, a new digital twin technology to maximize effectiveness of local government policies for solving societal issues Nov 26, 2024 10:51 JST
| TOYOTA GAZOO Racing reinforces WRC line-up with youth and experience for 2025 Nov 25, 2024 17:10 JST
| Toyota Submits Progress Report on Recurrence Prevention Measures Nov 25, 2024 15:43 JST
| TOPVISION Launches Prospectus for Transfer Listing from LEAP to the ACE Market Nov 25, 2024 15:00 JST
| MHI Thermal Systems Receives Order from Aisan Industry for Aquifer Thermal Energy Storage System for Its New Anjo Plant Nov 25, 2024 14:18 JST
| Oracle Red Bull Racing Driver Max Verstappen Wins Fourth Consecutive F1 Drivers' World Championship Nov 25, 2024 11:55 JST
| Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025 Nov 22, 2024 11:00 JST
| NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth Nov 21, 2024 22:59 JST
| Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan Nov 21, 2024 15:35 JST
| Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP Nov 21, 2024 09:00 JST
| ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study Nov 20, 2024 23:05 JST
| Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center Nov 20, 2024 15:30 JST
| Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan Nov 20, 2024 11:51 JST
| Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements Nov 20, 2024 10:24 JST
| Kingsoft Announces 2024 Third Quarter Results Nov 19, 2024 18:54 JST
| NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System Nov 19, 2024 15:30 JST
| Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings Nov 19, 2024 09:02 JST
|
More Latest Release >>
|